期刊文献+

基因工程干扰素与中药制剂并用抗乙型肝炎肝纤维化的临床研究 被引量:4

The Clinical Study on Treatment of Hepatic Fibrosis of Hepatitis B by IFN-α_1 and Chinese Medical Preparation
下载PDF
导出
摘要 为寻找治疗乙型肝炎肝纤维化的有效措施。方法;应用a1型基因工程干扰素(IFN-a1)和中药制剂治疗乙型肝炎肝纤维化患者40例,并观察治疗前后血清层粘蛋白、Ⅲ型前胶原、透明质酸、肝活检、B超、纤维胃镜等指标变化。结果:治疗3个月后,肝纤维化血清指标获得明显下降,与治疗前比较具有显著性差异(P<0.001);肝活检、B超、纤维胃镜证实肝纤维化获得改善;疗程结束6个月时,测定血清肝纤维化指标及白蛋白、球蛋白,IFN-a1效应型与无效应型比较也具有显著性差异(P<0.001)。结论:应用IFN-a1抑制乙型肝炎病毒复制、中药制剂抗肝纤维化具有较好疗效。 To find the effective method of curing hepatic fibrosis of hepatitis B. Methods: Using interferon a1and Chinese medical preparation to treat patients with hepatic fibrosis of hepatitis B and the comprehensive indexes,including levels of laminin, precollagen type Ⅲ and hyaluronic acid, liver puncture, ultrasonographic and fiber-gastroscopic examination were observed before and after treatment. Results:After 3 months of treatment, the fibroticindexes lowered obviously,in comparing with those before treatment, the difference was significant (P<0. 001 ).Liver biopsy, B-type ultrasonographic and fiber-gastroscopic examination proved that the hepatofibrosis was improved. The hepato-fibrotic indexes, blood albumin and globulin level were re-examined after 6 months, resultsshowed that the difference between the IFN-effective group and the IFN-ineffective group was significant, P<0.001. Conclusions:Beneficial effect might be obtained by using IFN-a1 to suppress the replication of hepatitis Bvirus and Chinese medical preparation to treat hepatic fibrosis.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 1997年第8期453-455,共3页 Chinese Journal of Integrated Traditional and Western Medicine
基金 贵州省科委"科委"重点项目 贵州省科委"九五"攻关项目
关键词 乙型肝炎 肝纤维化 干扰素 中药制剂 肝活检 层粘蛋白 hepatitis B hepatofibrosis interferon Chinese medical preparation liver biopsy laminin
  • 相关文献

同被引文献9

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部